Pharmacotherapy, i.e., the use of drugs in the prevention and treatment of disease, is predicated on the clinical application of pharmacodynamic and pharmacokinetic principles as influenced by patient-related variables. Many factors affect the drug response phenotype, e.g., age, gender, underlying disease, and genetic variations, and determine the individual effective dose of a drug required to produce a specific response and determine the success or failure of therapy.12
Genetic polymorphism can result in altered drug-receptor interactions or signaling pathways once a drug-receptor complex is formed causing inter-individual pharmacodynamic variations. Genomic variations can also affect oxidation/reduction and conjugation/hydrolysis reactions causing inter-individual pharmacokinetic variations. Furthermore, pharmacogenetic variations related to rare, unpredictable, i.e., idiosyncratic adverse effects have also been reported.
Because of these genomic variations, an individual may be hyporeactive, i.e., a drug’s usual effect is produced at an unexpectedly high dose or hyperreactive, i.e., the usual effect of a drug is produced at an unexpectedly low dose. An individual may also developed tolerance following repeated exposure to a drug requiring higher doses to maintain efficacy. Tolerance that develops rapidly, following the administration of only a few doses of a drug, is referred to as tachyphylaxis.
The individual effective dose of a drug intended to produce a specific effect is usually expressed in terms of milligram per kilogram of body weight. Manufacturers’ maximum recommended dose (MRD), by definition, is for a 75 kg (165 lbs.) healthy adult. Ultimately, in determining the optimum therapeutic dose of a drug for an individual one must consider the patient’s weight, as well as other factors such as dynamic and kinetics variables related to a specific patient.
Pregnancy and the fetus. Each drug appears to have a threshold concentration above which fetal abnormalities can occur and below which no adverse effects are discernible. Whether a drug reaches threshold concentrations in the fetus depends on a drug’s ability to translocate across the placental barrier. Genetic determinants of both the mother and the fetus will influence the extent to which a drug will affect the developing fetus.
Malformations are usually the result of fetal exposure to a drug during the first trimester. Exposure during the second and third trimesters primarily affects organ function. However, it is paramount to recognize that human teratogenicity is not predictable. Prescribing precautions can be found in the “Dosage and Administration,” “Contraindications,” “Warning and Precautions”, and “Adverse Effects” sections, and “Pregnancy” subsection of specific drug labeling.6
Lactation and the neonate. Milk is generally more acidic (pH 6.8) than plasma (pH 7.4); therefore, basic drugs become more concentrated in milk because of the phenomenon of pH trapping, while acidic drugs are limited in their ability to enter milk. Prescribing precautions can be found in the “Dosage and Administration,” “Contraindications,” “Warning and Precautions”, and “Adverse Effects” sections, and “Lactation” subsection of specific drug labeling.6
Females and males of reproductive potential. The FDA requires pregnancy testing or contraception before, during, or after therapy with some drugs and warnings about possible drug-related fertility effects. Prescribing precautions can be found in the “Dosage and Administration,” “Contraindications,” “Warning and Precautions”, and “Adverse Effects” sections, and “Females and Males of Reproductive Potential” subsection of specific drug labeling.6
Pediatric patients. Often there is a paucity of specific pharmacokinetic and pharmacodynamic data for the pediatric population. Dosage forms designed with the adult population in mind and the dosages cannot easily be individualized for children. Even when appropriate dosage forms for children are available palatability, resistance to taking medications, and adherence issues related to parent/guardian/caregiver may further hinder optimal therapy.
Although there are many rules and formulae to calculate drug dosages for children, weight-based dosing recommendations by manufacturers provide the most reasonable approach.6 The maximum safe dose of a drug should be carefully calculated for each child. Prescribing precautions can be found in the “Dosage and Administration,” “Contraindications,” “Warning and Precautions”, and “Adverse Effects” sections, and “Lactation” subsection of specific drug labeling.6
Geriatric patients. The use of drugs in elderly patients is another challenging area of clinical practice. The pharmacokinetics and pharmacodynamics of drugs are altered by age-related physiologic changes. The increased incidence of multiple chronic illnesses, the disproportionately high use of prescription and over-the-counter medications, inadequate nutrition, and poor adherence also contribute to the problem and lead to more adverse drug effects among the elderly.
Therapeutic target concentrations of drugs in the elderly population are also difficult to define because of marked inter-individual variations. Conservative dosing and close monitoring for dose-related effects is imperative. Prescribing precautions can be found in the “Dosage and Administration,” “Contraindications,” “Warning and Precautions” and “Adverse Effects” sections, and “Geriatric use” subsection of specific drug labeling.6
Patients with liver disease. In the presence of liver disease, adverse drug effects are primarily related to altered pharmacokinetic processes. To estimate the ability of the liver to metabolize drugs, determine the patient’s Child-Pugh score (Table 2).13-15 Prescribing precautions can be found in the “Dosage and Administration,” “Contraindications,” “Warning and Precautions” and “Adverse Effects” sections of specific drug labeling.6
|Tests/Symptoms||Score 1 point each||Score 2 points each||Score 3 points each|
|Total bilirubin in mg/dL||< 2.0||2.0-3.0||> 3.0|
|Serum albumin in mg/dL||> 3.5||2.8-3.5||< 2.8|
|Prothrombin time in seconds over control or the INR||< 4
(INR: < 1.7)
(INR: > 2.3)
Patients with chronic renal disease. Drug dosages are most commonly based on the estimated creatinine clearance determined by the Cockcroft-Gault equation, i.e., eCrCl in mL/min = (140 - age x weight in kg x 0.85 (for females) ÷ Scr in mg/dL x 72).16 The normal range for men and women ≥40 years of age is 107-139 mL/min and 87-107 mL/min, respectively. It is of note that after 20 years of age, eCrCl is reduced by 6.5 mL/min every 10 years.
The eCrCl is used as a surrogate of GFR (Figure 8). In general, if the eCrCl is >50 mL/min, no dosage adjustment is required; if it is 10-50 mL/min, some drugs should be reduced by 25-50%.; if it is <10 mL/min, some drugs should be reduced by up to 75%, while others should be avoided.16 Prescribing precautions can be found in the “Dosage and Administration,” “Contraindications,” “Warning and Precautions” and “Adverse Effects” sections of specific drug labeling.6
Non-adherence. It is a generally accepted that many patients do not adhere to their prescribed therapeutic regimen.17-20 Non-adherence can be intentional (actively choosing not to adhere) or unintentional (e.g., passively inconsistent medication-taking behavior including forgetfulness or carelessness). Determinants of non-adherence include the disease, the patient, the practitioner, the treatment regimen, economic factors, and the interaction of each of these factors.
A patient’s trust in the clinician and/or the treatment protocol as established during the office visit is important. Patients tend to be adherent if they have a good understanding of the illness and the therapy. Therefore, good communication between clinicians and patients is a major factor affecting adherence. A positive experience during the office visit, along with individualized regimens and good follow-up on the part of clinicians, improve adherence.
When an illness is serious or disabling, the patient will likely follow the therapeutic regimen. The longer the duration of treatment, the less likely it is that the patient will adhere to the regimen over time. This is especially true if symptoms are relieved before drug therapy is to be discontinued. The regimen itself may also be discouraging or confusing because of multiple drug use, scheduling of dosages, and side effects. Finally, cost may be a major contributing factor.
In children, the major reason for non-adherence is a dislike for the taste or smell of the medication. If it is frustrating to the parent/guardian/caregiver to give the medication, they are more likely to skip doses or discontinue the medication with the disappearance of symptoms. If the child is attending school, the regimen should be convenient and coordinated with the school schedule. Consider recommending specific times rather than generalize.
Common causes of non-adherence in elderly patients include failure to fill prescriptions due to transportation problems and expense. Other factors include a lack of trust or confidence in the doctor or therapy and poor comprehension of the regimen. Difficulty in opening packages or swallowing pills, poor memory, visual or hearing impairment may also contribute to non-adherence. Repetition of directions with written instructions and clear labeling are helpful.
Presctiptions. Drugs fall into two major categories: non-prescription, i.e., over-the-counter, and prescription drugs.1-3 Prescription drugs are further divided into legend drugs and scheduled drugs. Legend drugs require a prescription because they are considered to be potentially harmful if not used under supervision by a licensed practitioner. Legend drugs are known as such because their labels bear the legend “Caution: Federal Law Prohibits Dispensing Without a Prescription.”
The prescription of scheduled drugs, i.e., controlled substances, is even more strictly controlled by Federal regulations. A licensed practitioner who administers, prescribes, or dispenses controlled substances must register under Controlled Substances Act of 1970 with the Drug Enforcement Administration (DEA) and obtain a DEA number, which must be included on every prescription for a controlled substance.1-3 Many States have additional, sometimes more strict requirements.
A prescription is a written, verbal, or electronic order (1) from a licensed practitioner, (2) to a licensed pharmacist, (3) for a particular medication, (4) for a specific patient, (5) at a particular time. It has three components: a heading, a body, and a closing (Figure 9). These elements identify the prescriber and the patient; inform the pharmacist of the name, strength, and formulation of the drug to be dispensed; and provide instructions to the patient for self-administration of the drug.
As noted earlier, while drugs have the capacity to enhance health, they all have the potential to cause harm if prescribed or taken inappropriately. For this reasons it is recommended that healthcare professionals who prescribe medications exercise critical thinking skills to ensure the safe and effective use of therapeutic agents. The following steps, along with ongoing self-directed learning, reflect a disciplined approach to prescription writing and avoiding errors:21-23
Step 1- Be clear about the reasons for prescribing
Step 2 - Consider the patient’s drug history before prescribing
Step 3 - Identify other factors that might alter the benefits and risks of treatment
Step 4 - Take into consideration the patient’s expectations
Step 5 - Select efficacious, safe, and cost-effective drugs appropriate for the patient
Step 6 - Adhere to guidelines
Step 7 - Write unambiguous prescriptions
Step 8 - Monitor the beneficial and adverse effects of therapeutic agents
Step 9 - Communicate the reasons for and document prescribing decisions
Step 10 - Prescribe within limitations of knowledge, skills, and experience
Adverse drug effects (ADE). A noted earlier, there are no “absolutely” safe biologically active agents. Whether a drug will do harm to an individual depends on the patient’s age, genetic makeup, and preexisting conditions; and other drugs that the patient may be taking. A discussion of mechanisms of ADEs, common ADEs associated with drugs dispensed by U.S. community pharmacies, and less common ADEs in the head and neck area is presented elsewhere.24-26